Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

DBVT vs ASMB: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ASMB Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 6–3 Matrix Metrics)

ASMB Overall Winner 6-Pillar Tally: DBVT 2 – 4 ASMB Matrix Metrics: DBVT 3 – 6 ASMB

As of Nov 16, 2026, Assembly Biosciences, Inc (ASMB) is the stronger overall head-to-head candidate over DBV Technologies S.A. (DBVT) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). DBVT carries a Unified Composite Score of 30.9/100 (SELL) at $10.26 (N/M Forward P/E, -5577.0% operating margin), whereas ASMB carries 42.6/100 (HOLD) at $21.46 (N/M Forward P/E, -31.8% operating margin).

  • Growth vs. Quality Trade-Off: ASMB earns the overall head-to-head edge with a stronger Unified Composite Score (42.6/100 HOLD vs. DBVT 30.9/100 SELL) and 1.08β · 59% Vol risk profile, whereas DBVT leads top-line expansion (-42.9% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About DBVT vs ASMB
DBVT NASDAQ
DBV Technologies S.A.
Biological Products, (No Disgnostic Substances)
$10.26
-6.85% 1D
Market Cap $682.5M
TTM Revenue $3.7M
Forward P/E N/M
Beta / 30D Vol 1.17β · 77% Vol
Unified Composite Score
30.9 / 100 SELL
Tech 15.0 Fund 36.0 Flow 60.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 48
RSI-14: 47.9 · SMA20: $10.28 · SMA50: $10.78
ASMB NASDAQ Head-to-Head Winner
Assembly Biosciences, Inc
Pharmaceutical Preparations
$21.46
+1.63% 1D
Market Cap $414.5M
TTM Revenue $67M
Forward P/E N/M
Beta / 30D Vol 1.08β · 59% Vol
Unified Composite Score
42.6 / 100 HOLD
Tech 40.0 Fund 48.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 50
RSI-14: 50.1 · SMA20: $20.56 · SMA50: $22.95

6-Pillar Scorecard Institutional Category Breakdown (DBVT 2 – 4 ASMB)

Columns: Metric · DBVT · ASMB
1. Valuation Multiples ASMB
Forward P/E N/M N/M
Trailing P/E N/M 19.6x
PEG Ratio N/M N/M
EV / Revenue 140.3x 6.2x
2. Growth & Scale DBVT
Revenue Growth (YoY) -42.9% -72.6%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $3.7M $67M
Market Cap $682.5M $414.5M
3. Profitability & Quality ASMB
Gross Margin 100.0% 3.3%
Operating Margin -5577.0% -31.8%
Net Profit Margin 0.0% -16.6%
Return on Equity (ROE) -205.8% -4.6%
4. Balance Sheet & Cash Flow ASMB
Cash Generation (TTM) -$192M -$21M EBITDA
Cash Flow Margin N/A -31.7% EBITDA Mgn
Net Cash / Leverage $158M Net Cash $14.67 Book/Sh · -4.6% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning DBVT
Options Structure Phase SURGE UNCLASSIFIED
Current IV / %ile 64.5% (13th %ile) 109.3% (100th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase ACCUMULATION · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat ASMB
OpEx & R&D Intensity N/A 35.1% of Rev ($24M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: DBVT (3) vs ASMB (6)
Institutional Metric DBVT ASMB Criterion Row Edge
Market Capitalization
Scale
$682.5M $414.5M Larger Scale DBVT
Trailing P/E Ratio
Valuation
N/M 19.6x Lower Multiple ASMB
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-42.9% -72.6% Higher Growth DBVT
Operating Margin (TTM)
Profitability
-5577.0% -31.8% Higher Margin ASMB
Net Profit Margin
Profitability
0.0% -16.6% Higher Margin DBVT
Return on Equity (ROE)
Capital Efficiency
-205.8% -4.6% Higher ROE ASMB
52-Week Range Position
Momentum
9% ($9–$26) 11% ($19–$40) Stronger Trend ASMB
Beta / 30D Volatility
Risk Regime
1.17β · 77% Vol 1.08β · 59% Vol Lower Realized Risk ASMB
Unified Institutional Score
Composite Signal
30.9 / 100 (SELL) 42.6 / 100 (HOLD) Higher Composite ASMB
Trailing 12M Revenue (USD)
Operating Scale
$3.7M $67M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
100.0% 3.3% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 140.3x EV/Rev N/M PEG · 6.2x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$192M ($158M Net Cash) -$21M EBITDA ($14.67 Book/Sh · -4.6% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon DBVT +6.53 pp
DBVT: +13.37% · ASMB: +6.84%
3M Horizon DBVT +4.1 pp
DBVT: -29.09% · ASMB: -33.19%
6M Horizon ASMB +23.56 pp
DBVT: -45.28% · ASMB: -21.72%
1Y Horizon DBVT +18.13 pp
DBVT: -21.44% · ASMB: -39.57%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on DBVT vs ASMB. Trailing 12-month operating profitability (DBVT -5577.0% vs ASMB -31.8%) and valuation multiples (DBVT N/M vs ASMB N/M Forward P/E) are benchmarked directly in Pillar 4 below.

DBVT ADR TTM Benchmark FX-Normalized USD
TTM Revenue$3.7M
Gross Margin100.0%
Op. Margin-5577.0%
ROE / Fwd P/E-205.8% · N/M
ASMB ADR TTM Benchmark FX-Normalized USD
TTM Revenue$67M
Gross Margin3.3%
Op. Margin-31.8%
ROE / Fwd P/E-4.6% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
DBVT SURGE
5d in phase · OBV ACCUMULATION
Current IV 64.5%
IV Percentile 13th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow ACCUMULATION
Exact DBVT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ASMB UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 109.3%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ASMB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
DBVT Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $682.5M market capitalization and -5577.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ASMB Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $414.5M market capitalization and -31.8% operating margin.
OpEx & R&D Reinvestment 35.1% of Rev ($24M)
90D Engineering Disclosures 0 Published

Investor FAQ DBVT vs ASMB Key Questions & Quantitative Answers

As of Nov 16, 2026, Assembly Biosciences, Inc (ASMB) is the stronger overall head-to-head candidate over DBV Technologies S.A. (DBVT) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). DBVT carries a Unified Composite Score of 30.9/100 (SELL) at $10.26 (N/M Forward P/E, -5577.0% operating margin), whereas ASMB carries 42.6/100 (HOLD) at $21.46 (N/M Forward P/E, -31.8% operating margin). Growth vs. Quality Trade-Off: ASMB earns the overall head-to-head edge with a stronger Unified Composite Score (42.6/100 HOLD vs. DBVT 30.9/100 SELL) and 1.08β · 59% Vol risk profile, whereas DBVT leads top-line expansion (-42.9% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.

DBVT leads the Growth & Scale pillar: DBVT posts -42.9% YoY revenue growth and +0.0% YoY earnings growth on $3.7M TTM revenue (100.0% gross margin, -5577.0% operating margin), compared with ASMB at -72.6% YoY revenue growth and +0.0% YoY earnings growth on $67M TTM revenue (3.3% gross margin, -31.8% operating margin). On trailing 12-month operating scale, DBVT generates $3.7M in USD-normalized revenue versus $67M for ASMB. In operating R&D and SG&A reinvestment, DBVT deploys N/A (0 90-day corporate R&D disclosures) versus 35.1% of Rev ($24M) (0 disclosures) for ASMB.

ASMB screens cheaper on headline valuation multiples. DBVT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 140.3x EV/Revenue (unreported FCF margin), whereas ASMB trades at N/M Forward P/E, 19.6x Trailing P/E, N/M PEG, and 6.2x EV/Revenue (-31.7% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against DBVT (-205.8% ROE) versus ASMB (-4.6% ROE) capital efficiency.

In options market volatility and institutional positioning, DBVT carries 64.5% implied volatility (13th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a SURGE options structure phase (1.17β · 77% Vol realized risk). By comparison, ASMB carries 109.3% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.08β · 59% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.